Stock Watch: Summit’s Stock Plummets
Surprise Changes In The Middle Of A Phase III Study Are Probably Bad
Executive Summary
What on earth would make a biotech company change the primary endpoint half way through a Phase III program and not discuss it with the FDA? There are at least two scenarios, neither of them good.